CMS Makes Policy Waves With Pullback Of Longstanding TENS Coverage
This article was originally published in The Gray Sheet
The new finalized coverage policy for transcutaneous electrical nerve stimulation for treating chronic back pain is a rare decision by the agency to reverse coverage on an established technology, and is a new direction for the coverage-with-evidence-development program, observers say.
You may also be interested in...
Medtech Tools To Help Address Opioid Crisis Face Reimbursement Challenges
A wide variety of devices that could either serve as pain-relief substitutes for opioids, help manage opioid addictions or tackle distribution issues with the overly prescribed medications are facing reimbursement challenges at the US Centers for Medicare and Medicaid Services.
New Coverage-With-Evidence-Development Guidance In The Works Following MedCAC Meeting
The Medicare Evidence Development & Coverage Advisory Committee was charged May 16 with helping CMS better define the evidence threshold under which the agency should or should not pursue a coverage- with-evidence-development policy.
Groups Pained By CMS’ Use Of Coverage With Evidence Development In TENS Proposal
A recent Medicare coverage proposal for transcutaneous electrical nerve stimulation for chronic low-back pain is an unprecedented application of CED to turn back coverage of an established treatment, numerous parties tell CMS.